2seventy bio (NASDAQ:TSVT) Cut to Hold at Leerink Partnrs

Leerink Partnrs downgraded shares of 2seventy bio (NASDAQ:TSVT) from a strong-buy rating to a hold rating in a report released on Tuesday morning,Zacks.com reports.

Other research analysts also recently issued research reports about the stock. Leerink Partners reissued a “market perform” rating and set a $5.00 price objective (down previously from $9.00) on shares of 2seventy bio in a report on Tuesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of 2seventy bio in a research report on Friday, March 7th. One analyst has rated the stock with a sell rating, four have issued a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $6.83.

2seventy bio Price Performance

TSVT opened at $4.95 on Tuesday. The firm has a 50-day simple moving average of $2.64 and a two-hundred day simple moving average of $3.68. 2seventy bio has a 52 week low of $2.29 and a 52 week high of $5.99. The company has a market capitalization of $255.36 million, a PE ratio of -2.66 and a beta of 1.73.

Institutional Trading of 2seventy bio

Several institutional investors have recently added to or reduced their stakes in the company. Bank of America Corp DE lifted its stake in 2seventy bio by 317.1% in the fourth quarter. Bank of America Corp DE now owns 2,515,897 shares of the company’s stock worth $7,397,000 after purchasing an additional 1,912,771 shares during the last quarter. Regeneron Pharmaceuticals Inc. bought a new stake in 2seventy bio in the fourth quarter worth about $3,689,000. Geode Capital Management LLC lifted its stake in 2seventy bio by 1.1% in the third quarter. Geode Capital Management LLC now owns 1,176,244 shares of the company’s stock worth $5,553,000 after purchasing an additional 13,144 shares during the last quarter. State Street Corp raised its stake in shares of 2seventy bio by 1.5% during the third quarter. State Street Corp now owns 1,058,773 shares of the company’s stock valued at $4,997,000 after acquiring an additional 15,638 shares in the last quarter. Finally, Eversept Partners LP raised its stake in shares of 2seventy bio by 0.6% during the fourth quarter. Eversept Partners LP now owns 1,003,678 shares of the company’s stock valued at $2,951,000 after acquiring an additional 5,599 shares in the last quarter. Institutional investors own 93.90% of the company’s stock.

2seventy bio Company Profile

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.